Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain
09.05.2018
Following Successful Completion of LANTERN-1 Clinical Trial.
News
Immusoft Granted Orphan Drug Designation for Treatment of Rare Childhood Disease
02.05.2018
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).
We are delighted to announce the opening of our new office in Philadelphia, PA, USA
01.05.2018
In addition to the corporate headquarters in London, UK and operational offices in EU, the new office space in Philadelphia will enable IAG’ team to continue expansion of our global network of scientific and medical collaborators, while being within easy reach of strategic partners.
Bonti Announces Scientific Presentation at Premier Aesthetic Plastic Surgery Conference
25.04.2018
EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018.
Nine IAG’s abstracts, reflecting clinical research innovations of the past year, were accepted for presentation in the industry’s leading #rheumatology and #oncology scientific meetings
15.03.2018
The works selected for publication are based on the results of innovative clinical research studies, which involve state-of-the-art and cutting-edge advanced imaging techniques, quantitative methodologies for assessment of treatment efficacy, including some that are based on machine learning and AI concepts.